Stefano Guzzinati

Dr. Stefano Guzzinati

Azienda Zero, Padua, Italy
orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in Gut
Verified
Journal Article
Closed access
MZManuel Zorzi
Manuel Zorzi
UFUgo Fedeli
Ugo Fedeli
ESElena Schievano
Elena Schievano
EBEmanuela Bovo
Emanuela Bovo
SGStefano Guzzinati
Stefano Guzzinati
ATAngelo Paolo Dei Tos
Angelo Paolo Dei Tos
Objective: Colorectal cancer (CRC) screening programmes based on the guaiac faecal occult blood test (gFOBT) reduce CRC-specific mortality. Several studies have shown higher sensitivity with the faecal immunochemical test (FIT) compared with gFOBT. We carried out an ecological study to evaluate the impact of FIT-based screening programmes on CRC mortality. Design: In the Veneto Region (Italy), biennial FIT-based screening programmes that invited 50–69-year-old residents were introduced in different areas between 2002 and 2009. We compared CRC mortality rates from 1995 to 2011 between the areas where screening started in 2002–2004 (early screening areas (ESA)) and areas that introduced the screening in 2008–2009 (late screening areas (LSA)) using Poisson regression models. We also compared available data on CRC incidence rates (1995–2007) and surgical resection rates (2001–2012). Results: Before the introduction of screening, CRC mortality and incidence rates in the two areas were similar. Compared with 1995–2000, 2006–2011 mortality rates were 22% lower in the ESA than in the LSA (rate ratio (RR)=0.78; 95% CI 0.68 to 0.89). The reduction was larger in women (RR=0.64; CI 0.51 to 0.80) than in men (RR=0.87; CI 0.73 to 1.04). In the ESA, incidence and surgery rates peaked during the introduction of the screening programme and then returned to the baseline (2006–2007 incidence) or dropped below initial values (surgery after 2007). Conclusions: FIT-based screening programmes were associated with a significant reduction in CRC mortality. This effect took place much earlier than reported by gFOBT-based trials and observational studies.

1 October 2015 in European Journal of Cancer
Verified
Journal Article
Open access
LAL.A. Anderson
L.A. Anderson
ATA. Tavilla
A. Tavilla
HBHermann Brenner
Hermann Brenner
SLS. Luttmann
S. Luttmann
CNC. Navarro
C. Navarro
ROR. Otter
R. Otter
European regional variation in cancer survival was reported in the EUROCARE-4 study for patients diagnosed in 1995-1999. Relative survival (RS) estimates are here updated for patients diagnosed with cancer of the oesophagus, stomach and small intestine from 2000 to 2007. Trends in RS from 1999-2001 to 2005-2007 are presented to monitor and discuss improvements in patient survival in Europe. EUROCARE-5 data from 29 countries (87 cancer registries) were used to investigate 1- and 5-year RS. Using registry-specific life-tables stratified by age, gender and calendar year, age-standardised 'complete analysis' RS estimates by country and region were calculated for Northern, Southern, Eastern and Central Europe, and for Ireland and United Kingdom (UK). Survival trends of patients in periods 1999-2001, 2002-2004 and 2005-2007 were investigated using the 'period' RS approach. We computed the 5-year RS conditional on surviving the first year (5-year conditional survival), as the ratio of age-standardised 5-year RS to 1-year RS. Oesophageal cancer 1- and 5-year RS (40% and 12%, respectively) remained poor in Europe. Patient survival was worst in Eastern (8%), Northern (11%) and Southern Europe (10%). Europe-wide, there was a 3% improvement in oesophageal cancer 5-year survival by 2005-2007, with Ireland and the UK (3%), and Central Europe (4%) showing large improvements. Europe-wide, stomach cancer 5-year RS was 25%. Ireland and UK (17%) and Eastern Europe (19%) had the poorest 5-year patient survival. Southern Europe had the best 5-year survival (30%), though only showing an improvement of 2% by 2005-2007. Small intestine cancer 5-year RS for Europe was 48%, with Central Europe having the best (54%), and Ireland and UK the poorest (37%). Five-year patient survival improvement for Europe was 8% by 2005-2007, with Central, Southern and Eastern Europe showing the greatest increases (⩾9%). Survival for these cancer sites, particularly oesophageal cancer, remains poor in Europe with wide variation. Further investigation into the wide variation, including analysis by histology and anatomical sub-site, will yield insights to better monitor and explain the improvements in survival observed over time.

1 November 2018 in American Journal of Gastroenterology
Verified
Journal Article
Closed access
PDF file
MRMassimo Rugge
Massimo Rugge
RGRobert M. Genta
Robert M. Genta
MFMatteo Fassan
Matteo Fassan
EVElisa Valentini
Elisa Valentini
ICIrene Coati
Irene Coati
PMPeter Malfertheiner
Peter Malfertheiner
Gastritis OLGA-staging ranks the risk for gastric cancer (GC) in progressive stages (0–IV). This long-term follow-up study quantifies the GC risk associated with each OLGA stage. Consecutive patients (7436) underwent esophagogastroscopy (T-0), with mapped gastric biopsies, OLGA staging, and H. pylori status assessment. Patients with neoplastic lesion (invasive or non-invasive) at the index endoscopy (and/or within 12 months) were excluded. All patients were followed-up (T-1) by combining different sources of clinical/pathological information (Regional Registries of: (i) esophagogastroduodenoscopies; (ii) pathology reports; (iii) cancer, (iv) mortality). The endpoint was histologically documented development of gastric epithelial neoplasia. At T-0, the patients’ distribution by OLGA stage was: Stage 0 = 80.8%; Stage I = 12.6%; Stage II = 4.3%; Stage III = 2.0%; Stage IV = 0.3%; H. pylori infection was detected in 25.9% of patients. At the end of the follow-up (mean/median = 6.3/6.6 years), 28 incident neoplasia were documented (overall prevalence = 0.60 per 103/person-years; low-grade intraepithelial neoplasia = 17/28; high-grade intraepithelial neoplasia = 4/28; GC = 7/28). By OLGA stage at the enrollment, the rate of incident neoplasia was: Stage 0 = 1 case; rate/103 person-years = 0.03; 95%CI: 0.004–0.19; Stage I = 2 cases; rate/103 person-years = 0.34; 95%CI: 0.09–1.36; Stage II = 3 cases; rate/103 person-years = 1.48; 95%CI: 0.48–4.58; Stage III = 17 cases; rate/103 person-years = 19.1; 95%CI: 11.9–30.7; Stage IV = 5 cases; rate/103 person-years = 41.2; 95%CI: 17.2–99.3. Multivariate analysis including gender, age, H. pylori status, and OLGA stage at enrollment only disclosed OLGA stage as predictor of neoplastic progression (OLGA stage III: HR = 712.4, 95%CI = 92.543–5484.5; OLGA stage IV: HR = 1450.7, 95%CI = 166.7–12626.0). Among 7436 patients, OLGA stages at the enrollment correlated significantly with different risk for gastric neoplasia. Based on the obtained results, gastritis staging is a critical adjunct in endoscopy follow-up protocols aimed at GC secondary prevention.

1 October 2015 in European Journal of Cancer
Verified
Journal Article
Closed access
CLCome Lepage
Come Lepage
RCRiccardo Capocaccia
Riccardo Capocaccia
MHMonika Hackl
Monika Hackl
VLValerie Lemmens
Valerie Lemmens
EMEsther Molina
Esther Molina
CWC. White
C. White

1 April 2009 in European Journal of Cancer
Verified
Journal Article
Closed access
AVArduino Verdecchia
Arduino Verdecchia
SGStefano Guzzinati
Stefano Guzzinati
SFSilvia Francisci
Silvia Francisci
RARoberta De Angelis
Roberta De Angelis
FBFreddie Bray
Freddie Bray
MSMilena Sant
Milena Sant

1 July 2003 in British Journal of Cancer
Verified
Journal Article
Open access
FSfor the Cancer and AIDS Registry Linkage Study
for the Cancer and AIDS Registry Linkage Study
LMLuigino DAL MASO
Luigino DAL MASO
SFS Franceschi
S Franceschi
Jerry PoleselJerry Polesel
Jerry Polesel
CBC Braga
C Braga
GRG Rezza
G Rezza
A record linkage was carried out between the Italian Registry of AIDS and 19 Cancer Registries (CRs), which covered 23% of the Italian population, to estimate the overall cancer burden among persons with HIV or AIDS (PWHA) in Italy, according to various characteristics. Observed and expected numbers of cancer and standardised incidence ratios (SIRs) were assessed until 1998 in 12 104 PWHA aged 15-69 years, for a total of 60 421 person-years. Significantly increased SIRs were observed for Kaposi's sarcoma (KS, 1749-fold higher than the general population), non-Hodgkin's lymphomas (NHL, 352), and invasive cervical cancer (22). SIR was significantly elevated also for cancer of the anus (34), lung cancer (2.4), brain tumours (4.4), Hodgkin's disease (16), and leukaemias (5.3). The majority of lung and brain cancers were not histologically confirmed, and the possibility of misclassification with KS or NHL cannot be ruled out. The SIR for all non-AIDS-defining cancers was 2.2 in men and 2.5 in women. Intravenous drug users showed significantly more elevated SIRs for lung cancer (9.4), and brain tumours (6.7) than other transmission categories (SIR=1.4 and 2.3, respectively). This study confirmed increased SIRs for haemolymphopoietic neoplasms other than NHL in PWHA, although many-fold smaller than for NHL. An association with human papillomavirus-related cancers was also confirmed.